Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The mutator phenotype describes a process by which tumour cells are proposed to evolve genetic alterations that contribute to the acquisition of the various attributes that are required for tumour progression. Here, Lawrence Loeb updates this hypothesis, focusing on how DNA sequencing has informed the current view of the mutator phenotype in cancer.
There seem to be several overlapping processes that induce resistance to antibiotics for bacteria and chemotherapy for tumour cells. This Perspective discusses how our understanding of bacterial resistance to antibiotics might inform our understanding of the resistance of tumours to therapy.
This article discusses the possible function of the super elongation complex (SEC) and the DOT1 H3K79 methyltransferase complex (DotCom) in leukaemia that is induced by translocation of mixed lineage leukaemia (MLL).
Over the past 40 years, genetic studies have provided important insights into the genetic architecture of common cancers. Recent genome-wide studies have identified numerous cancer susceptibility genes and led to a shift from single-gene models to multigenic models of cancer risk.
Clinical trial results with matrix metalloproteinase (MMP) inhibitors have been poor. So, which MMPs are validated drug targets with a crucial role in disease pathogenesis and which MMPs are actually proteins that have unacceptable deleterious effects when inhibited (anti-targets)?
